Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
11/25/2021 11/26/2021 11/29/2021 11/30/2021 12/01/2021 Date
86.65(c) 85.01(c) 85.61(c) 83.86(c) 85.84 Last
1 285 804 3 118 500 2 621 498 4 920 304 2 784 537 Volume
-0.76% -1.89% +0.71% -2.04% +2.36% Change
More quotes
Estimated financial data (e)
Sales 2021 37 724 M 42 712 M 42 712 M
Net income 2021 6 216 M 7 038 M 7 038 M
Net Debt 2021 9 372 M 10 612 M 10 612 M
P/E ratio 2021 17,4x
Yield 2021 3,85%
Sales 2022 40 081 M 45 381 M 45 381 M
Net income 2022 7 470 M 8 458 M 8 458 M
Net Debt 2022 5 879 M 6 656 M 6 656 M
P/E ratio 2022 14,6x
Yield 2022 4,06%
Capitalization 105 B 119 B 119 B
EV / Sales 2021 3,04x
EV / Sales 2022 2,77x
Nbr of Employees 99 412
Free-Float 88,4%
More Financials
Company
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular,... 
Sector
Pharmaceuticals
Calendar
12/01 | 08:00amAnalyst Meeting - Vaccines Day
More about the company
Ratings of Sanofi
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about SANOFI
09:41aSANOFI : Gets a Buy rating from JP Morgan
MD
04:25aSanofi Reaffirms Mid-Term Sales Growth Target for Vaccines Unit; to Acquire Origimm Bio..
MT
02:01aSanofi Reaffirms Mid-Term Jab Sales Guidance on Strength of Core Franchises
MT
01:31aVACCINES INVESTOR EVENT : Sanofi reiterates confidence in strong growth outlook and showca..
AQ
01:15aSanofi to Buy Skin-Focused Origimm Biotechnology
MT
01:06aHealthcare group Sanofi to buy Origimm Biotechnology to boost vaccines business
RE
01:00aSanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based ..
AQ
11/29SANOFI : UBS gives a Buy rating
MD
11/26Hoechst Industrial Park to Be Put Up Sale With Multibillion-Euro Price Tag -Handelsblat..
DJ
11/26Sanofi India to Sell Two Brands to Topical Formulation Manufacturer
MT
11/24SANOFI : Receives a Buy rating from UBS
MD
11/22Sanofi To Deploy Baidu's mRNA Algorithm For Clinical Development
MT
11/22Baidu Licenses mRNA Vaccine Algorithm to Sanofi
MT
11/22SANOFI : invests $180 million equity in Owkin's artificial intelligence and federated lear..
PU
11/22Baidu, Sanofi Enter mRNA-Focused License Deal
MT
More news
News in other languages on SANOFI
11:54aCAC40 : confirme son rebond, Wall Street dans le vert
09:21aDPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 01.12.2021 - 15.15 Uhr
09:18aCAC40 : décembre démarre en fanfare, secteur auto surpondéré
05:13aSANOFI : La valeur du jour à Paris Sanofi continue de miser sur les vaccins
04:38aCAC40 : gagne 1%, les inquiétudes sur Omicron se dissipent
More news
Analyst Recommendations on SANOFI
More recommendations
Stock Trading Strategies
SANOFI - 03/05
A support level that should be taken advantage of
BUY
More Stock Trading Analysis
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | MarketScreener
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 85,84 €
Average target price 106,88 €
Spread / Average Target 24,5%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI6.56%118 651
JOHNSON & JOHNSON-0.92%410 501
ROCHE HOLDING AG16.39%337 091
PFIZER, INC.45.97%301 579
NOVO NORDISK A/S65.17%243 741
ELI LILLY AND COMPANY46.91%224 871